T 1993/23 (Glycopyrrolate composition/NOVARTIS) of 07.10.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T199323.20251007
- Date of decision
- 7 October 2025
- Case number
- T 1993/23
- Online on
- 5 November 2025
- Petition for review of
- -
- Application number
- 10164976.2
- IPC class
- A61K 31/402A61P 11/00A61K 31/4704
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
- Applicant name
- Novartis AG
- Opponent name
- Hoffmann Eitle
Teva UK Limited
PGA S.P.A.
isarpatent - Patent- und Rechtsanwälte Behnisch
Barth Charles Hassa Peckmann und Partner mbB
STADA Arzneimittel AG
Orion Corporation
ORION PHARMA
European Oppositions Limited
N.V. Nederlandsch Octrooibureau
Dr. Schön, Neymeyr & Partner Patentanwälte mbB
HGF Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Inventive step - main request (no)
Inventive step - auxiliary request (no)
Amendment to case - suitability of amendment to address issues (no)
Amendment to appeal case - justification by party (no)
Amendments after summons
Amendments - exceptional circumstances (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.